Balanced news tone
News Sentiment
PLYX sentiment intelligence
Polaryx Therapeutics, Inc. Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
56
Balanced news tone
58 relevant articles
News tone and price action are not far from neutral.
76/100 classification confidence.
directly relevant articles
high-authority source matches
-2.1% over one week, -1.7% over four weeks, trend inactive, and below fair value.
Polaryx Therapeutics Announces Chief Medical Officer Resignation
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
76/100 classification
One-week reaction
-2.1%
Price reacting lower
Trend fit
Trend inactive
-1.7% over four weeks
Fair value
-44.2%
Below fair value
Value support
Sentiment Mix
Positive, neutral, negative
Positive
18
Neutral
34
Negative
6
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
The Globe and Mail
Direct company coverage
Polaryx Therapeutics Announces Chief Medical Officer Resignation
Polaryx Therapeutics, Inc. announced the immediate resignation of its Chief Medical Officer, Lisa Bollinger, MD, effective July 19, 2026. The company stated that this departure is not expected to impact clinical timelines, regulatory plans, or development strategy, with existing
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 22 Jul 2026 21:12
- Source
- The Globe and Mail
Kalkine
Direct company coverage
Polaryx Therapeutics, Inc. Common Stock (NASDAQ: PLYX) Stock Price, News & Analysis
This article provides an overview of Polaryx Therapeutics, Inc. (NASDAQ: PLYX) stock, including its current price, daily range, and a snapshot of its fundamental metrics such as previous close, market capitalization, and trading volume. It also offers sections for financial chart
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 Jul 2026 15:09
- Source
- Kalkine
www.marketscreener.com
Direct company coverage
Polaryx Therapeutics, Inc. Announces Resignation of Lisa Bollinger from Chief Medical Officer, Effective July 19, 2026
Polaryx Therapeutics, Inc. announced the resignation of Lisa Bollinger, MD, as Chief Medical Officer, effective July 19, 2026. The company does not expect her departure to impact its clinical timelines, regulatory plans, or development strategy. A search for a successor has begun
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 21 Jul 2026 04:31
- Source
- www.marketscreener.com
Stock Titan
Direct company coverage
Polaryx Therapeutics (PLYX) schedules 2026 virtual annual meeting and proposal deadline
Polaryx Therapeutics (PLYX) has announced that its 2026 Annual Meeting of Stockholders will be held virtually on September 10, 2026. The record date for stockholders eligible to vote is July 27, 2026. The deadline for stockholder proposals and director nominations to be included
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jul 2026 12:10
- Source
- Stock Titan
Bitget
Direct company coverage
Polaryx Therapeutics sets 2026 annual shareholder meeting as virtual event
Polaryx Therapeutics has announced that its 2026 annual stockholders meeting will be held virtually on September 10, 2026. Shareholders recorded as of July 27, 2026, will be eligible to vote. The company plans to release further details regarding the matters to be voted upon in a
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jul 2026 12:02
- Source
- Bitget
Market source
Industry context
Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 16 Jul 2026 18:49
- Source
- Market source
Market source
Industry context
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 07:00
- Source
- Market source
MarketBeat
Direct company coverage
What is HC Wainwright's Forecast for PLYX Q2 Earnings?
HC Wainwright forecasts Polaryx Therapeutics (NASDAQ: PLYX) will report Q2 2026 EPS of ($0.05) and has reiterated a Buy rating with a $7.00 price target. The firm's longer-term estimates indicate continued losses through FY2027, with quarterly projections remaining consistent aro
- Tone
- Positive 64/100
- Event
- Earnings
- Published
- 13 Jul 2026 05:41
- Source
- MarketBeat
MarketBeat
Direct company coverage
Polaryx Therapeutics (NASDAQ:PLYX) Downgraded by Wall Street Zen to "Sell"
Polaryx Therapeutics (NASDAQ:PLYX) has been downgraded from a "hold" to a "sell" rating by Wall Street Zen, adding a bearish sentiment to existing analyst coverage. This contrasts with a "buy" rating and $7.00 price target from HC Wainwright, leading to an overall "Hold" consensu
- Tone
- Negative 39/100
- Event
- Analyst action
- Published
- 12 Jul 2026 17:40
- Source
- MarketBeat
Bitget
Direct company coverage
Investment firm H.C. Wainwright announced today the launch of initial coverage research on biopharmaceutical company Polaryx Therapeutics Inc.
Investment firm H.C. Wainwright has initiated coverage on biopharmaceutical company Polaryx Therapeutics Inc., assigning a "Buy" rating and a target price of $7 for its stock. This move suggests optimism among analysts regarding the company's future development and potential valu
- Tone
- Positive 77/100
- Event
- Analyst action
- Published
- 11 Jul 2026 22:41
- Source
- Bitget
Moomoo
Direct company coverage
Polaryx Therapeutics Initiated at Buy by HC Wainwright & Co.
HC Wainwright & Co. has initiated coverage on Polaryx Therapeutics with a "Buy" rating. This indicates an optimistic outlook from the analytical firm regarding the company's future performance or potential. Investors may see this as a positive signal for Polaryx Therapeutics.
- Tone
- Positive 70/100
- Event
- Analyst action
- Published
- 10 Jul 2026 08:09
- Source
- Moomoo
Investing.com
Direct company coverage
H.C. Wainwright initiates Polaryx Therapeutics stock with buy rating
H.C. Wainwright has initiated coverage on Polaryx Therapeutics (NASDAQ:PLYX) with a Buy rating and a price target of $7.00, representing a significant upside. The firm highlighted PLX-200, a repurposed oral drug targeting fatal pediatric central nervous system lysosomal storage d
- Tone
- Positive 70/100
- Event
- Analyst action
- Published
- 09 Jul 2026 11:40
- Source
- Investing.com
Investing.com Nigeria
Direct company coverage
H.C. Wainwright initiates Polaryx Therapeutics stock with buy rating By Investing.com
H.C. Wainwright initiated coverage on Polaryx Therapeutics (NASDAQ:PLYX) with a Buy rating and a $7.00 price target, representing a potential 175% upside. The firm highlighted Polaryx's lead drug candidate, PLX-200, which targets fatal pediatric central nervous system lysosomal s
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 09 Jul 2026 11:17
- Source
- Investing.com Nigeria
TradingView
Direct company coverage
Free cash flow per share of Polaryx Therapeutics, Inc. – FWB:1V8
The article provides a title focusing on the free cash flow per share of Polaryx Therapeutics, Inc. (FWB:1V8) on the Frankfurt Stock Exchange. The content primarily consists of website navigation, disclaimers, and links to various financial tools and community features rather tha
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 03 Jul 2026 20:17
- Source
- TradingView
TradingView
Direct company coverage
Operating cash flow per share of Polaryx Therapeutics, Inc. – FWB:1V8
The article focuses on the operating cash flow per share of Polaryx Therapeutics, Inc., traded on the Frankfurt Stock Exchange under the symbol 1V8. It appears to be a financial data page from TradingView, indicating the market is closed with no current trades. The content primar
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 03 Jul 2026 16:40
- Source
- TradingView
TradingView
Direct company coverage
Why Tenet Healthcare (THC) Stock Is Up Today
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jul 2026 07:00
- Source
- TradingView
TradingView
Direct company coverage
Enterprise value to revenue forward of Polaryx Therapeutics, Inc. – NASDAQ:PLYX
The article focuses on the "Enterprise value to revenue forward" metric for Polaryx Therapeutics, Inc., traded on Nasdaq under the symbol PLYX. It appears to be a financial data snippet from a larger platform, indicating a specific financial ratio for the company.
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 28 Jun 2026 04:11
- Source
- TradingView
TradingView
Direct company coverage
Enterprise value to EBIT forward of Polaryx Therapeutics, Inc. – NASDAQ:PLYX
This article displays the Enterprise Value to EBIT forward for Polaryx Therapeutics, Inc. (NASDAQ: PLYX) through a TradingView snapshot. The market is currently closed for this stock, and no trades have been made. The information is presented within a financial data analysis cont
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Jun 2026 10:39
- Source
- TradingView
TradingView
Direct company coverage
Price to sales forward of Polaryx Therapeutics, Inc. – NASDAQ:PLYX
The article discusses the forward price-to-sales ratio for Polaryx Therapeutics, Inc. (NASDAQ: PLYX) on TradingView. It provides a brief financial overview of the company, indicating the market is closed with no trades. The article is a snippet related to financial data availabil
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Jun 2026 01:10
- Source
- TradingView
TradingView
Direct company coverage
Polaryx Therapeutics, Inc. Actuals & Estimates (NASDAQ:PLYX)
Polaryx Therapeutics, Inc. (NASDAQ:PLYX) is currently trading at $2.31, experiencing a recent decline. Analysts have a maximum and minimum price target of $10.00 for PLYX. The company has a market capitalization of $109.36 million and is scheduled to release its next earnings rep
- Tone
- Negative 38/100
- Event
- Earnings
- Published
- 26 Jun 2026 02:10
- Source
- TradingView
TradingKey
Direct company coverage
Polaryx Therapeutics Ord Shs (PLYX) Earnings Forecast: Future EPS & Revenue Growth Estimates
Polaryx Therapeutics Ord Shs (PLYX) has received a "Buy" rating from analysts, with one analyst predicting a significant upside of +321.94% for its target price. The article provides an overview of the company's earnings forecast and analyst ratings, noting that relevant financia
- Tone
- Positive 78/100
- Event
- Earnings
- Published
- 17 Jun 2026 08:39
- Source
- TradingKey
Market source
Direct company coverage
Cooper Companies Stock: Is COO Underperforming the Healthcare Sector?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Jun 2026 07:00
- Source
- Market source
Benzinga
Direct company coverage
Polaryx Therapeutics Inc (PLYX) Stock Price, Quote, News & History
This page provides a comprehensive overview of Polaryx Therapeutics Inc. (PLYX) stock, including its current price, historical data, recent news, and key financial statistics. It details the company's focus on developing therapies for rare pediatric lysosomal storage disorders an
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 13 Jun 2026 21:40
- Source
- Benzinga
Market source
Direct company coverage
Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Jun 2026 07:00
- Source
- Market source
Finviz
Direct company coverage
PLYX - Polaryx Therapeutics Inc Short Interest
This article provides detailed short interest and financial data for Polaryx Therapeutics Inc (PLYX). It includes current stock performance metrics, key financial indicators like market cap, sales, and EPS, alongside insider ownership and institutional transactions, and short int
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 09 Jun 2026 07:41
- Source
- Finviz
Moomoo
Direct company coverage
Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of SOTERIA Phase 2 Basket Trial
Polaryx Therapeutics has closed a $10 million private placement equity financing round. This funding is intended to support the launch of its SOTERIA Phase 2 basket trial. The trial will evaluate PLX-200, an oral therapeutic, for its efficacy in treating multiple rare indications
- Tone
- Positive 75/100
- Event
- Market update
- Published
- 30 May 2026 06:08
- Source
- Moomoo
Stock Titan
Direct company coverage
MStone affiliate of Polaryx Therapeutics (PLYX) buys 88K common shares
MStone Partners Healthcare Limited, an affiliate of Polaryx Therapeutics (PLYX) and founded by Polaryx CEO Alex Keun Mo Yang, purchased 88,453 shares of Polaryx common stock in a private placement. This transaction, which occurred on May 27, 2026, generated $360,000 in gross proc
- Tone
- Positive 71/100
- Event
- Market update
- Published
- 29 May 2026 16:40
- Source
- Stock Titan
Investing.com Nigeria
Direct company coverage
Polaryx Therapeutics closes $10 million PIPE financing By Investing.com
Polaryx Therapeutics has successfully closed a $10 million Private Investment in Public Equity (PIPE) financing, selling over 2.5 million shares at approximately $4.00 per share. The biotechnology company plans to use these proceeds, along with existing cash, to fund the initiati
- Tone
- Positive 78/100
- Event
- Balance sheet
- Published
- 29 May 2026 02:10
- Source
- Investing.com Nigeria
Quantisnow
Direct company coverage
PLYX - Polaryx Therapeutics Inc. stock news, filings & ratings
Polaryx Therapeutics (PLYX) stock is currently priced at $3.28, up 6.84%. Recent notable events include the CEO's purchase of $360,004 worth of shares, the closing of a $10 million private placement equity financing, and multiple U.S. FDA Fast Track Designations for its lead cand
- Tone
- Positive 71/100
- Event
- Market update
- Published
- 29 May 2026 02:10
- Source
- Quantisnow
Investing.com
Direct company coverage
Polaryx Therapeutics CEO’s Mstone buys $360,003 in PLYX stock
Mstone Partners Healthcare Ltd, an entity where Polaryx Therapeutics CEO Alex Keun Mo Yang serves as founder and CEO, purchased 88,453 shares of Polaryx Therapeutics (PLYX) common stock for $360,003 in a private placement. This transaction occurred on May 27, 2026, at $4.07 per s
- Tone
- Positive 69/100
- Event
- Market update
- Published
- 29 May 2026 00:09
- Source
- Investing.com